Dr Christopher Nave is a founding partner of a leading Australian life science investment firm Brandon Capital Partners, and chief executive of the Medical Research Commercialisation Fund.
Dr Nave was director of commercialisation at the Baker IDI Heart and Diabetes Institute in Melbourne, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. He was also a manager of the biotechnology team at Melbourne Ventures, the commercialisation company of the University of Melbourne.
In 2014, Dr Nave was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award for his contribution to the industry.
He holds a first-class Honours degree in Science, and has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston.
